Trial Profile
Phase II Study of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Muparfostat (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Progen Pharmaceuticals Limited
- 22 Oct 2007 Status changed from in progress to completed.
- 24 Sep 2007 Primary and secondary endpoints not achieved: results reported by Progen Pharmaceuticals.
- 24 Sep 2007 Results data are available.